



Biophytis[®]

LIVE HEALTHIER LONGER

AGM

May 10, 2021



May 2021 | Euronext: ALBPS – Nasdaq: BPTS

Forward Looking Statements

All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and other risks discussed in the Company’s registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the “SEC”), which are available for review at <http://www.sec.gov/>.

Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to publicly update or review such statements to reflect events or circumstances after the date of this presentation, except as required by law.

Agenda


1	Quorum 2021 AGM Second call
2	Pipeline & key milestones
3	2020 Key financial highlights
4	2021 AGM resolutions & vote results



AGM May 10 2021 – Second call quorum

- Biophytis' second call combined AGM took place today behind closed doors, due to the COVID-19 pandemic.
- **The shareholders taking part in the vote owned collectively 24 994 687 shares, or 22,37% of the share capital, and 22.82% of the voting rights.**

Our clinical pipeline is progressing and expanding since last year



- Second generation drug candidates, BIO103 and BIO203, are life-cycle extension candidates in the preclinical Phase



Key programs milestones

- | | | |
|-------------------------------------|-----------------|--|
| <input checked="" type="checkbox"/> | COVA | Started in Belgium, Brazil, France and US |
| <input checked="" type="checkbox"/> | COVA | Completion of patient enrollment (Part 1) in January 2021 |
| <input checked="" type="checkbox"/> | COVA | Interim analysis of Part 1 (50 patients) in Q1 2021 |
| <input checked="" type="checkbox"/> | COVA | Approvals to start Part 2 in Q1 2021 |
| <input type="checkbox"/> | COVA | Interim analysis for Part 2 (155 patients) expected before end Q2 2021 |
| <input type="checkbox"/> | COVA | Topline results expected in Q2 2021 |
| <input checked="" type="checkbox"/> | SARA-INT | (Phase 2) patient enrollment completed in March 2020 |
| <input checked="" type="checkbox"/> | SARA-INT | Last patient out (LPO) completed in Dec 2020 |
| <input type="checkbox"/> | SARA-INT | Topline trial results expected in Q2 2021 |

Successful US IPO in addition to PIPEs on Euronext totaling €40M

U.S. Initial Public Offering

In February 2021, the Company closed an initial public offering on the NASDAQ (BPTS)

Public offering gross proceeds totaling at closed

\$20.1M

(€16.6M)

Oversubscribed

3X

2020 Euronext Financings

The Company successfully closed four private placement transactions

Private placement gross proceeds totaled

€23.4M

Stabilized loss in 2020 despite the start of COVA, thanks to lower G&A spendings

Consolidated Operating Results (M€)	2019	2020
Net Research and Development expenses	9.1	9.9
General and administrative expenses	6.6	4.0
Operating loss	(15.7)	(13.9)
Net financial loss	(2.1)	(3.1)
Loss before tax	(17.8)	(17.0)
Income tax	-	-
Net loss	(17.8)	(17.0)
Non diluted weighted average number of shares outstanding, except treasury shares	16 882 661	59 974 486
Basic and non diluted loss per share (€/share)	(1,05)	(0,28)

Cash and current financial assets improved from 6.8M€ to 18.8M€

Consolidated Assets (M€)	2019	2020
Patents and software	2.4	2.7
Property, plant and equipment	0.2	0.1
Other non-current financial assets	0.4	0.4
Total non-current assets	3.0	3.2
Other receivables	7.9	5.3
Other current financial assets	0.5	12.9 (*)
Cash and cash equivalents	6.3	5.8
Total current assets	14.7	24.0
Total assets	17.7	27.2

(*) of which 12.5M€ of term deposit

Cash flows: higher resources mainly due to successful financing activities

Consolidated Net cash (use)/sources (M€)	2019	2020
Operating activities	(15.3)	(9.9)
Investing Activities (inc. 12.5M€ in term deposit in 2020)	(0.3)	(12.7)
Financing Activities	7.5	22.1
Net increase (decrease) in cash and cash equivalents exc. term deposits	(8.1)	(0.5)

Cash, cash equivalent & other current financial assets – Beginning balance	14.4	6.8
Cash, cash equivalent & other current financial assets – Ending balance	6.8	18.8
Net increase (decrease) in cash and cash equivalents inc. term deposits	(7.6)	12.0

Net equity significantly strengthened, and financial debts decreased

Consolidated Liabilities (M€)	2019	2020
Share capital	4.8	20.2
Premiums related to the share capital	45.2	17.8
Accumulated deficit	(39.7)	(14.1)
Net loss	(17.8)	(17.1)
Total shareholders' equity	(7.5)	6.8
Employee benefit obligations	0.1	0.2
Non-current financial liabilities	5.4	1.8
Total non-current liabilities	5.5	2.0
Current financial liabilities	9.8	7.3
Provisions	-	1.4
Trade payables	7.9	8.0
Tax and social liabilities	1.4	1.4
Derivative financial instruments	0.5	-
Other creditors and miscellaneous liabilities	0.2	0.3
Total current liabilities	19.7	18.4
Total Liabilities & Shareholders' Equity	17.7	27.2

Ordinary Resolutions

- #1: Approval of the financial accounts for the financial year ended on December 31st, 2020,
- #2: Approval of the consolidated financial accounts for the financial year ended on December 31st, 2020,
- #3: Allocation and distribution of net income for the financial year ended on December 31st, 2020,
- #4: Approval of the regulated agreements referred to in articles L. 225-38 and seq. of the French commercial Code,
- #5: Approval of the amendment of the intellectual property rights transfer agreement dated May 22nd, 2019 entered into between the Company and its President,
- #6: Approval of the conclusion of compensation agreements entered into between the Company and Directors of the Company,
- #7: Determination of Directors' attendance fees,
- #8: Approval of depreciation and expenses under article 39-4 of the French general tax Code for the financial year ended on December 31, 2020,
- #9: Approval of the discharge to be granted to the President and members of the Board of Directors of the Company for the financial year ended on December 31, 2020,
- #19: Authorization to be given to the Board of Directors to purchase the Company's own shares in accordance with article L. 22-10-62 of the French commercial Code,
- #26: Renewal of Mr. Dimitri Batsis' term of office as director;
- #27: Renewal of Mrs. Nadine Coulm's term of office as director;
- #28: Renewal of Mr. Stanislas Veillet's term of office as director;
- #29: Renewal of Grant Thornton's term of office as joint statutory auditor;
- #30: Non-renewal of the mandate of INSTITUT DE GESTION ET D'EXPERTISE COMPTABLE - IGEC as deputy auditor of the Company;
- #31: Powers to carry out formalities

Extraordinary Resolutions- Delegation to issue new shares and debt

- #10: Delegation of authority to the Board of Directors under the provisions of Article L. 225-129-2 of the French commercial Code to decide to issue shares and/or securities giving immediate or future access to the share capital or giving the right to a claim security with waiver of preferential subscription right and without indication of beneficiaries, by way of a public offering
- #11: Delegation of authority to the Board of Directors to decide either to issue shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security with preferential subscription right, or to incorporate profits, reserves or premiums into the share capital,
- #12: Delegation of authority to the Board of Directors to decide either to issue shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security with preferential subscription right, or to incorporate profits, reserves or premiums into the share capital,
- #13: Delegation of authority to the Board of Directors to issue shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security with waiver of the preferential subscription right for the benefit of a category of beneficiaries,
- #14: Delegation of authority to the Board of Directors to decide to issue shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security with waiver of the preferential subscription right for the benefit of a category of persons ensuring the underwriting of the Company's share capital that may result form of an equity financing line,
- #15: Delegation of authority to the Board of Directors to decide to issue shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security with the waiver of the preferential subscription right by way of an offer to qualified investors or a restricted circle of investors within the meaning of article L. 411-2 1° of the French monetary and financial Code (private investment) and within the limit of 20% of the share capital per year,

Extraordinary Resolutions — Other Delegations

- #16: Authorization to be granted to the Board of Directors to increase the number of shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security in accordance with the provisions of article L. 225-135-1 of the French commercial Code, in the event of implementation of the delegations of authority referred to in the six previous resolutions ("over-allocation option"),
- #17: Delegation of powers to the Board of Directors to proceed, within the framework of the provisions of article L. 225-129-1 of the French commercial Code, to a share capital increase with waiver of the preferential subscription right for the benefit of the Company's employees who are members of the Company Savings Plan to set up by the Company under the conditions provided for in article L. 3332-18 and following of the French labour Code,
- #18: Setting the overall cap on authorizations to issue shares and/or securities giving immediate or deferred access to share capital or giving entitlement to a debt security,
- #20: Decisions to be made following article L. 225-248 of the French commercial Code (to continue corporate activity despite losses)
- #21: Authorization to be granted to the Board of Directors to reduce the Company's share capital by cancelling shares acquired under any share buyback program,
- #22: Delegation of authority to the Board of Directors to decide to issue warrants (bons de souscription d'actions) (BSA2021) with waiver of the preferential subscription right to the benefit of categories of beneficiaries,
- #23: Authorization to be granted to the Board of Directors to decide to issue warrants (bons de souscription de parts de créateur d'entreprise) (BSPCE2021) with waiver of the preferential subscription right to the benefit of categories of beneficiaries,
- #24: Authorization to be granted to the Board of Directors to proceed with the free allocation of shares to be issued or existing (AGA2021) with waiver of the preferential subscription right to the benefit of categories of beneficiaries,
- #25: Authorization to be granted to the Board of Directors to grant options to under and/or purchase shares (Options2021) to the benefit of categories of beneficiaries,

AGO votes results

Resolution N°1 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 806 012	97,582%	
Against	614 757	2,418%	
Abstain	235 455	0,918%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°2 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 836 943	97,703%	
Against	583 826	2,297%	
Abstain	235 455	0,918%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°3 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 704 173	97,291%	
Against	687 984	2,709%	
Abstain	264 067	1,029%	
Void	0	0,000%	
Blank	0	0,000%	

AGO votes results

Resolution N°4 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	21 937 682	24 994 687	21,96%
Exclusions	3 718 542	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	21 007 791	96,989%	
Against	652 105	3,011%	
Abstain	277 786	1,266%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°5 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	21 937 682	24 994 687	21,96%
Exclusions	3 718 542	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	19 216 166	89,149%	
Against	2 338 990	10,851%	
Abstain	382 526	1,744%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°6 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	21 937 682	24 994 687	21,96%
Exclusions	3 718 542	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	19 114 673	88,854%	
Against	2 397 695	11,146%	
Abstain	425 314	1,939%	
Void	0	0,000%	
Blank	0	0,000%	

AGO votes results

Resolution N°7 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 619 585	93,359%	
Against	1 680 243	6,641%	
Abstain	356 396	1,389%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°8 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 808 675	97,634%	
Against	601 162	2,366%	
Abstain	246 387	0,960%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°9 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 585 001	96,876%	
Against	792 916	3,124%	
Abstain	278 307	1,085%	
Void	0	0,000%	
Blank	0	0,000%	

AGO votes results

Resolution N°19 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 667 437	93,093%	
Against	1 755 875	6,907%	
Abstain	232 912	0,908%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°26 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 735 611	93,778%	
Against	1 574 918	6,222%	
Abstain	345 695	1,347%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°27 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 783 394	93,943%	
Against	1 533 423	6,057%	
Abstain	339 407	1,323%	
Void	0	0,000%	
Blank	0	0,000%	

AGO votes results

Resolution N°19 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 667 437	93,093%	
Against	1 755 875	6,907%	
Abstain	232 912	0,908%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°26 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 735 611	93,778%	
Against	1 574 918	6,222%	
Abstain	345 695	1,347%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°27 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 783 394	93,943%	
Against	1 533 423	6,057%	
Abstain	339 407	1,323%	
Void	0	0,000%	
Blank	0	0,000%	

AGO votes results

Resolution N°28 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 350 574	95,935%	
Against	1 031 870	4,065%	
Abstain	273 780	1,067%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°29 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 549 141	97,097%	
Against	733 983	2,903%	
Abstain	373 100	1,454%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°30 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 515 143	97,160%	
Against	716 632	2,840%	
Abstain	424 449	1,654%	
Void	0	0,000%	
Blank	0	0,000%	

AGO votes results

Resolution N°31 (AGO)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 580 676	97,053%	
Against	746 409	2,947%	
Abstain	329 139	1,283%	
Void	0	0,000%	
Blank	0	0,000%	

AGE votes results

Resolution N°10 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 269 001	87,712%	
Against	3 119 859	12,288%	
Abstain	267 364	1,042%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°11 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 354 664	92,016%	
Against	2 026 413	7,984%	
Abstain	275 147	1,072%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°12 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 338 911	87,878%	
Against	3 081 439	12,122%	
Abstain	235 874	0,919%	
Void	0	0,000%	
Blank	0	0,000%	

AGE votes results

Resolution N°13 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 381 263	88,048%	
Against	3 038 135	11,952%	
Abstain	236 826	0,923%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°14 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 470 516	88,374%	
Against	2 955 964	11,626%	
Abstain	229 744	0,895%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°15 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 616 591	90,141%	
Against	2 473 537	9,859%	
Abstain	566 096	2,206%	
Void	0	0,000%	
Blank	0	0,000%	

AGE votes results

Resolution N°16 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 642 315	89,650%	
Against	2 614 019	10,350%	
Abstain	399 890	1,559%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°17 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 433 318	92,757%	
Against	1 829 932	7,243%	
Abstain	392 974	1,532%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°18 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	23 916 126	94,911%	
Against	1 282 234	5,089%	
Abstain	457 864	1,785%	
Void	0	0,000%	
Blank	0	0,000%	

AGE votes results

Resolution N°20 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 633 551	96,868%	
Against	796 555	3,132%	
Abstain	226 118	0,881%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°21 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	24 231 390	96,100%	
Against	983 281	3,900%	
Abstain	441 553	1,721%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°22 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting Exclusions	25 656 224 0	24 994 687 0	21,96% 0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 499 021	88,832%	
Against	2 828 496	11,168%	
Abstain	328 707	1,281%	
Void	0	0,000%	
Blank	0	0,000%	

AGE votes results

Resolution N°23 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 417 211	88,899%	
Against	2 799 398	11,101%	
Abstain	439 615	1,713%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°24 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 453 479	88,833%	
Against	2 822 566	11,167%	
Abstain	380 179	1,482%	
Void	0	0,000%	
Blank	0	0,000%	

Resolution N°25 (AGE)			
	Number of Voting rights	Number of Shares	Shares (%)
Voting	25 656 224	24 994 687	21,96%
Exclusions	0	0	0,00%
	Number of Voting rights	Percentage	Resolution Adopted
For	22 430 065	88,951%	
Against	2 785 997	11,049%	
Abstain	440 162	1,716%	
Void	0	0,000%	
Blank	0	0,000%	

CONTACTS:

- Stanislas Veillet – CEO
stanislas.veillet@biophytis.com
- Evelyne NGUYEN – CFO
evelyne.nguyen@biophytis.com

Thank you

Investor relations: investors@biophytis.com

Website: www.biophytis.com